Comparison
While Exenatide is used for type 2 diabetes treatment to improve glycemic control and modestly reduce body weight through GLP-1–like insulinotropic and glucagonostatic effects6768, FOXO4-DRI acts as a senolytic in preclinical models by promoting apoptosis of senescent cells, improving tissue function and healthspan measures in aged animals38.
While Exenatide works as a 39-amino-acid exendin-4 peptide originally isolated from Gila monster venom that acts as a long-acting GLP-1 receptor agonist resistant to DPP-4 degradation67, FOXO4-DRI is a D-retro-inverso peptide derived from a FOXO4 region that competes with endogenous FOXO4 for binding to p53, thereby releasing p53 to trigger apoptosis selectively in senescent cells38.
Exenatide is 39 amino acids long, whereas FOXO4-DRI is shorter as it has a length of amino acids. Exenatide is made up of a sequence of sequence data not available in the current dataset. FOXO4-DRI is made up of a sequence of sequence data not available in the current dataset.
Exenatide
Not assigned in the current dataset.
FOXO4-DRI
FOXO4